TORONTO, Nov. 19, 2024 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the "Company” or "PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company, today announced that the FDA granted ...

PharmaTher owns 49% of Sairiyo Therapeutics Inc., which focuses on advancing the clinical development of an improved and patented enteric-coated orally bioavailable formulation of cepharanthine ...

Pharmadrug (TSE:PHRX) has released an update. PharmaDrug’s Sairiyo Therapeutics has successfully completed a stability study of its reformulated cepharanthine, PD-001, paving the way for its ...